[1] |
Li XZ, Nie Z, Yang Q, et al. Effect of valproic acid on oxidative stress after acute spinal cord injury in rats[J]. Orthopedic Journal of China, 2012, 20(14): 1323-1327.
|
[2] |
Liu Q, Xia YZ, Yan Y. Protease activated receptor 2(PAR2) regulates GFAP and vimentin expression at the early stage of glia scar formation after spinal cord injury[J]. Chinese Journal of Nervous and Mental Diseases, 2013, 39(7): 421-426.
|
[3] |
Rowland JW, Hawryluk GW, Kwon B, et al. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon[J]. Neurosurg Focus, 2008, 25(5): E2. DOI: 10.3171/FOC.2008.25.11.E2.
|
[4] |
Knoller N, Auerbach G, Fulga V, et al. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results[J]. J Neurosurg Spine, 2005, 3(3): 173-181. DOI: 10.3171/spi.2005.3.3.0173.
|
[5] |
Bethea JR, Nagashima H, Acosta MC, et al. Systemically administered IL-10 reduces TNF-α production and significantly improves functional recovery following traumatic spinal cord injury in rats[J]. J Neurotrauma, 1999, 16(10): 851-863. DOI: 10.1089/neu.1999.16.851.
|
[6] |
Octavio JG, Javier C, Antonio I, et al. Early effects of modulating nuclear factor-kB activation on traumatic spinal cord injury in rats[J]. Ann N Y Acad Sci, 2005, 1053(1): 148-150. DOI: 10.1196/annals.1344.012.
|
[7] |
Rulli A, Antognelli C, Prezzi E, et al. A possible regulatory roleof 17beta-estradiol and tamoxifen on glyoxalase I and glyoxalase II genes expression in MCF7 and BT20 human breast cancer cells[J]. Breast Cancer Res Treat, 2006, 96(2): 187-196. DOI: 10.1007/s10549-005-9078-7.
|
[8] |
Kim KM, Kim YS, Jung DH, et al. Increased glyoxalase I levels inhibit accumulation of oxidative stress and an advanced glycation end product in mouse mesangial cells cultured in high glucose[J]. Exp Cell Res, 2012, 318(2): 152-159. DOI: 10.1016/j.yexcr.2011.10.013.
|
[9] |
Cheng WL, Tsai MM, Tsai CY, et al. Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression[J]. PLoS One, 2012, 7(3): e34352. DOI: 10.1371/journal.pone.0034352.
|
[10] |
Megan J, Douglas W. Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy[J]. Transl Res, 2012, 159(5): 355-365. DOI: 10.1016/j.trsl.2011.12.004.
|
[11] |
Bethea JR, Dietrich WD. Targeting the host inflammatory response in traumatic spinal cord injury[J]. Curr Opin Neurol, 2002, 15(3):355-360. DOI: 10.1097/00019052-200206000-00021.
|
[12] |
Ndisang JF, Vannacci A, Rastogi S. Oxidative stress and inflammation in obesity, diabetes, hypertension, and related cardiometabolic complications[J]. Oxid Med Cell Longev, 2014, 2014(S): 506948. DOI: 10.1155/2014/506948.
|
[13] |
Hellenbrand DJ, Reichl KA, Travis BJ, et al. Sustained interleukin-10 delivery reduces inflammation and improves motor function after spinal cord injury[J]. J Neuroinflammation, 2019, 16(1): 93-107. DOI: 10.1186/s12974-019-1479-3.
|
[14] |
Koushki D, Latifi S, Javidan AN, et al. Efficacy of some non-conventional herbal medications (sulforaphane, tanshinone IIA, and tetramethylpyrazine) in inducing neuroprotection in comparison with interleukin-10 after spinal cord injury: a meta-analysis[J]. J Spinal Cord Med, 2015, 38(1): 13-22. DOI: 10.1179/2045772314Y. 0000000 215.
|
[15] |
Badner A, Vidal PM, Hong J, et al. Endogenous interleukin-10 deficiency exacerbates vascular pathology in traumatic cervical spinal cord injury[J]. J Neurotrauma, 2019, 36(15): 2298-2307. DOI: 10.1089/neu.2018.6081.
|
[16] |
Ni GY, Chen S, Yuan JW, et al. Comparative proteomic study reveals the enhanced immune response with the blockade of interleukin 10 with anti-IL-10 and anti-IL-10 receptor antibodies in human U937 cells[J]. PloS One, 2019, 14(3): e0213813. DOI: 10.1371/journal.pone.0213813.
|
[17] |
Brewer KL, Bethea JR, Yezierski RP. Neuropretective effects of interleukin-10 following excitotoxic spinal cord injury[J]. Exp Neurol, 1999, 159(2): 484-493. DOI: 10.1006/exnr.1999.7173.
|
[18] |
Oruckaptan HH, Ozisik P, Atilla P, et al. Systemic administration of interleukin-10 attenuates early ischemic response following spinal cord ischemia reperfusion injury in rats[J]. J Surg Res, 2009, 155(2): 345-356. DOI: 10.1016/j.jss.2008.07.013.
|